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Abstract
Most statistical tests for treatment effects used in randomized clinical trials with
survival outcomes are based on the proportional hazards assumption, which often
fails in practice. Data from early exploratory studies may provide evidence of non-
proportional hazards which can guide the choice of alternative tests in the design of
practice-changing confirmatory trials. We study a test to detect treatment effects in a
late-stage trial which accounts for the deviations from proportional hazards suggested
by early-stage data. Conditional on early-stage data, among all tests which control the
frequentist Type I error rate at a fixed α level, our testing procedure maximizes the
Bayesian prediction of the finite-sample power. Hence, the proposed test provides a
useful benchmark for other tests commonly used in presence of non-proportional haz-
ards, for example weighted log-rank tests. We illustrate the approach in a simulations
based on data from a published cancer immunotherapy phase III trial.
Keywords : design of clinical trials; censored data; proportional hazards; tests of hypothe-
ses; decision theory.
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1 Introduction
Researchers often use data generated by exploratory clinical studies to specify the proto-
col of randomized confirmatory phase III trials. Data predictive of the confirmatory trial
outcomes, including early estimates of treatment effects, are used to choose the primary
endpoints (Go´mez et al., 2014), the sample size (Lindley, 1997), the target populations (Lee
and Wason, 2018), and other aspects of the study design (Brody, 2016). Still, in most cases
prior information is not used to specify in the protocol, as mandated by regulatory agencies,
which hypothesis testing procedure will be used in the final analyses to provide evidence
of treatment effects. Agencies such as the U.S. Food and Drug Administration require the
control of Type I and II errors at pre-specified rates (Food and Drug Administration, 1998).
In Phase III trials, standard tests, such as Mantel’s log-rank, are often selected even for
studies where prior data suggests their underlying assumptions will be violated (Royston and
Parmar, 2013; Alexander et al., 2018). For survival endpoints, methods related to the log-
rank test are prevalent. Asymptotically, this is the most powerful test with a proportional
hazards alternative (Fleming and Harrington, 2011). However, the proportional hazards
assumption is often violated in practice, contributing to false-negative findings (Royston
and Parmar, 2013), invalidating sample size calculations (Barthel et al., 2006), and affecting
interim analyses (van Houwelingen et al., 2005).
Data from early-stage studies can inform about deviations from the assumption of pro-
portional hazards, suggesting the use of alternative methods (Royston and Parmar, 2013).
Several extensions and alternatives are available to replace Mantel’s test, such as weighted
(Fleming and Harrington, 2011) or adaptive log-rank tests (Yang and Prentice, 2010), and re-
stricted mean survival tests (Royston and Parmar, 2013). Some of these procedures identify
the most powerful test against specific alternatives, but these may not represent estimates
from early stage analyses. Moreover, their optimality typically holds in a large-sample sense
(e.g. in the local limit, for weighted log-rank tests; Fleming and Harrington, 2011).
We develop a statistical test to detect treatments effects in late-stage trials, accounting
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for deviations from the proportional hazards assumption indicated by early-phase studies
(e.g. phase II trials). The proposed test does not belong to the weighted log-rank family
or other common classes of tests. Starting from decision theory principles (Berger, 2013),
we derive it as the solution of a constrained decision problem (Ventz and Trippa, 2015):
conditional on early-stage data, the test maximizes the predicted finite-sample power among
all tests which control the frequentist Type I error rate of the late-stage study at a fixed α
level. More precisely, the test maximizes the Bayesian predictive probability that the null
hypothesis will be correctly rejected at the end of the confirmatory trial. The test is therefore
a useful benchmark for other procedures applicable in presence of non-proportional hazards.
As a motivating example we consider the analysis of a randomized trial with delayed
treatment effects on survival outcomes. This is a characteristic which occurs when the
treatment requires an induction period before it starts to exert therapeutic effects. When
treatment effects are delayed, the hazard functions are not proportional and they separate
across arms only later during follow-up (Fine, 2007). Initially overlapping survival curves (c.f.
Figure 1a) are well documented in trials of cancer immunotherapies (Chen, 2013; Alexander
et al., 2018). They can also be observed in other settings, such as in studies of breast cancer
(Mehta et al., 2012) and melanoma (Robert et al., 2015) chemotherapies.
2 Example
We consider data on the survival times of the 361 patients with head and neck carcinomas
that participated in CheckMate 141 study (Ferris et al., 2016), a Phase III trial that ran-
domized patients to receive nivolumab, a novel cancer immunotherapy, or standard of care
(SOC) in a 2:1 ratio. We reconstructed the individual-level data of this trial from Figure
1a of Ferris et al. (2016) by means of the DigitizeIt (TM) software (version 2.2) and the
data extraction method of Guyot et al. (2012). Figure 1a shows the resulting Kaplan-Meier
curves, which compare survival probabilities between the two study arms. These do not
3
clearly separate in the initial 3-4 months of follow-up, a signal of delayed treatment effects.
[FIGURE 1 ABOUT HERE]
3 Planning a late-stage trial
We plan a late-stage randomized trial with a survival end-point and a sample size of n
patients. This will generate data x = (t, d, a) to test if the treatment has positive effects on
the primary outcome. Here, t = (t1, . . . , tn) are the observed follow-up times, d = (d1, . . . , dn)
are the corresponding censoring indicators (di = 1 if ti is censored, while di = 0 if an event
was observed), and a = (a1, . . . , an) are the study arm indicators (ai = 0 or ai = 1 if the i-th
patient is randomized to the control or treatment arm). Patients are assigned to arms with
a fixed randomization probability. We assume that censoring times are non informative in
the sense of Heitjan and Rubin (1991) and independent of treatment assignment.
For design purposes, we specify a model for the distribution that will generate the data
x. This is described by a density pθ(x) that depends on a parameters vector θ ∈ Θ. Here
θ may be infinite-dimensional if the model is semi- or non-parametric. Typically, pθ(x) will
have the form
pθ(x) =
n∏
i=1
rai(1− r)1−aihai(ti; θ)1−diSai(ti; θ)gi(ti)diGi(ti)1−di , (1)
where: r ∈ (0, 1) is the probability of assignment to arm a = 1, ha(t; θ) > 0 is the hazard
function of arm a = 0, 1 (for example, in the exponential model, ha(t; θ) = θa, θ = (θ0, θ1) ∈
Θ = (0,+∞)2); Sa(t; θ) = exp
(
− ∫ t
0
ha(s; θ)ds
)
is the corresponding survival function;
finally, gi(t) and Gi(t) are the density and (left-continuous) survival function of the i-th
patient’s censoring time. Here, the censoring mechanism is taken as known, a common
assumption when planning new experiments (Chow et al., 2007). We will later discuss that
this assumption is not used in the development of the proposed testing procedure.
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We consider the non-parametric null hypothesis H0 : P ∈ P0, where P is the true data-
generating distribution of x (i.e. P (A) is the probability that x ∈ A) and P0 is the class
of all distributions which are invariant with respect to permutations of the treatment arm
assignments. Hence, P ∈ P0 if its likelihood function p(x) is such that p(t, d, a) = p(t, d, a′)
for all a′ obtained by permuting the elements of a.
The alternative hypothesis is defined from model (1) as H1: P has density pθ(x) for
some θ ∈ Θ1, where Θ1 is a subset of Θ. For example, Θ1 may include all θ such that
h0(t; θ) 6= h1(t; θ), such that the median of S1(t; θ) is greater than that of S0(t; θ), or such
that the restricted mean survival in arm a = 1 is greater than in arm a = 0 (Royston and
Parmar, 2013).
According to this definition of the null hypothesis, regardless of whether the model pθ(x) is
correct or not, when treatment has no effect the treatment assignments a1, . . ., an provide no
information about the follow-up times t and censoring indicators d. Hence, the distribution
of the data does not change if these are arbitrarily permuted (Fisher, 1935; Dawid, 1988;
Good, 2006; Pesarin and Salmaso, 2010).
This definition covers distributions in which the observations (t1, d1, a1), . . . , (tn, dn, an)
from individual patients cannot be considered independent and identically distributed. For
example, this may happen when recruiters selectively enroll patients in the trial based on
interim analyses or results from other studies published during the enrollment period, or when
treatment effects are confounded by trends in latent covariates, amendments of inclusion-
exclusion criteria, and improvements in adjuvant therapies (Tamm and Hilgers, 2014). In
such cases, if treatment has no effects, p(x) should still remain invariant if the treatment
arm indicators are permuted.
It is now necessary to choose which α-level test ϕ(x) should be used in the late-stage
trial. A (randomized) test of H0 is a function ϕ(x) ∈ [0, 1] such that if data x is observed,
then H0 is rejected with probability ϕ(x) (Lehmann and Romano, 2006). A test is non-
randomized if it can only attain the values 0 and 1 (only non-randomized tests are used in
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practice, but here we also consider randomized tests because of their analytic advantages).
The expected value EP [ϕ(x)] =
∫
Xn ϕ(x)dP (x) is equal to the probability of rejecting H0
with data generated from the distribution P . If α ∈ (0, 1) and EP [ϕ(x)] ≤ α for all P ∈ P0,
then ϕ(x) is said to have level α.
4 Bayesian expected power
Different α-level tests are usually compared with respect to their power functions piϕ(θ) =∫
ϕ(x)pθ(x)dx or its asymptotic approximations. If ϕ1(x) and ϕ2(x) are two α-level tests for
H0 versus the simple alternative H1 : θ = θ1, for some fixed θ1 ∈ Θ1, then ϕ1(x) is preferred
to ϕ2(x) if piϕ1(θ1) ≥ piϕ2(θ1). Such comparisons are difficult for composite alternative
hypotheses. In fact, uniformly most powerful α-level tests, i.e. tests achieving the maximum
power across all alternative models θ1 ∈ Θ1, may not exist (Lehmann and Romano, 2006).
To address this problem, some authors proposed to compare tests with respect to their
average power. Specifically, the average power of a test ϕ(x) is
∫
Θ1
piϕ(θ)p(θ)dθ, where
p(θ) is a distribution weighting each value of θ ∈ Θ based on pre-experimental information
(Spiegelhalter and Freedman, 1986; O’Hagan et al., 2005). With this metric, two tests are
always comparable. Additionally, α-level tests maximizing the average power always exist,
although these may be randomized (Chen et al., 2007).
To allow data xe = (te, de, ae) from an early-stage trial to inform comparisons between
tests, we consider a data-dependent prior p(θ|xe). Several approaches have been proposed
to incorporate historical data in a prior distribution, including power priors (Ibrahim et al.,
2015), meta-analytic priors (Schmid et al., 2016), and commensurate priors (Hobbs et al.,
2011). For simplicity, we define p(θ|xe) as the posterior distribution p(θ|xe) ∝ L(θ;xe)p(θ),
where, letting ne be the early-stage trial sample size,
L(θ;xe) =
ne∏
i=1
hae,i(te,i; θ)
1−de,iSae,i(te,i; θ), (2)
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while p(θ) is a prior distribution on Θ whose choice depend on the specific application context.
In doing so, we implicitly assume identical treatment effects and survival distributions in the
early- and late-stage trials.
Extending the average power approach, the Bayesian expected power (BEP) of ϕ(x) is
BEPϕ =
∫
Θ1
piϕ(θ)p(θ|xe)dθ, (3)
a concept first introduced by Brown et al. (1987) and “rediscovered” by several authors
(Liu, 2018). It is simple to observe that BEPϕ = Pr(ϕ(x) rejects H0 and θ ∈ Θ1|xe), the
probability, conditional on the early-stage data, that ϕ(x) will correctly reject H0 at end of
the late-stage trial. This is often called the probability of success of the trial (Liu, 2018).
From the point of view of decision theory (Berger, 2013), the BEP is the expected value
of the utility function u(θ, ϕ, x) = I{θ ∈ Θ1}ϕ(x) (if H1 holds, then the utility increases
with the probability ϕ(x) of rejecting H0). Indeed,
BEPϕ =
∫ ∫
u(θ, ϕ, x)pθ(x)p(θ|xe)dxdθ. (4)
The problem of choosing which test to apply in the late-stage trial can thus be stated as
a constrained maximization problem (Ventz and Trippa, 2015): among α-level tests we
optimize the BEP.
5 Tests maximizing the expected power
We identify an α-level test with maximum Bayesian expected power. Explicit expressions
have been obtained for the case where the set P0 which defines the null hypothesis (H0 :
P ∈ P0) is finite (Chen, 2013). Instead, our choice of H0 includes all distributions that are
invariant with respect to permutations of treatment assignment a1, . . ., an. We show that the
maximum-BEP test is a permutation test. This is obtained by computing or approximating
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the distribution of real-valued test statistic T (x) across all permutations of the treatment
assignments, while the values of the follow-up times t and censoring indicators d are kept
fixed at the observed values.
To be more formal, for each permutation σ of (1, . . . , n), we denote with aσ = (aσ(1), . . .,
aσ(n)) the vector obtained by re-ordering the elements of a = (a1, . . . , an) according to σ.
Moreover, if T (x) is any real-valued statistics, for each x = (t, d, a) we let T (1)(x) ≤ · · · ≤
T (n!)(x) be the ordered values of T (t, d, aσ) as σ varies across all n! permutations.
The α-level permutation test ϕ(x) of H0 based on the test statistic T (x) can now be
defined as follows. First, let kα = n! − bαn!c, so that, for each x, T (kα)(x) is the (1 − α)-
level quantile of T (j)(x) for j = 1, . . . , n!. Second, let M+(x) =
∑n!
j=1 I{T (j)(x) > T (kα)(x)}
and M0(x) =
∑n!
j=1 I{T (j)(x) = T (kα)(x)} be the number of T (j)(x)’s greater or equal to
T (kα)(x), respectively. Then, the permutation test ϕ(x) is defined by letting ϕ(x) = 1 when
T (x) > T (kα)(x), ϕ(x) = 0 when T (x) < T (kα)(x), and ϕ(x) = (αn! −M+(x))/M0(x) < 1
when T (x) = T (kα)(x). This satisfies EP [ϕ(x)] = α for all P ∈ P0 (Lehmann and Romano,
2006, Theorem 15.2.1).
Proposition 5.1. Let ϕ(x) be the α-level permutation test of H0 : P ∈ P0 based on the test
statistic T (x) = q(x), where q(x) is the density of Q 6∈ P0, Q(A) =
∫
A
q(x)dµ(x) for every
measurable A, and µ is invariant with respect to permutations σ assignments a1, . . ., an. If
ϕ′(x) is another α-level test of H0, then EQ[ϕ′(x)] ≤ EQ[ϕ(x)], i.e. ϕ(x) has higher power
under the alternative H1 : P = Q.
Proof. Let Pµ ⊆ P0 be the set of all distributions dominated by µ that are invariant
with respect to permutations of treatment assignment (a non-empty set, since it includes
q′(t, d, a) =
∑
σ q(t, d, aσ)/n!). By Theorem 2 of Lehmann et al. (1949), for every test
ϕ′(x) such that EP [ϕ′(x)] ≤ α for all P ∈ Pµ, ϕ(x) guarantees EQ[ϕ′(x)] ≤ EQ[ϕ(x)].
Now, if ϕ′(x) is an α-level test of H0, then EP [ϕ′(x)] ≤ α for all P ∈ Pµ and therefore
EQ[ϕ
′(x)] ≤ EQ[ϕ(x)].
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To proceed, let P (H1|xe) =
∫
Θ1
p(θ|xe)dθ > 0 be the prior probability of the alternative
hypothesis H1. Also,
q(x) =
∫
Θ1
pθ(x)
p(θ|xe)
P (H1|xe)dθ (5)
is the density of the predictive distribution of x conditional on θ ∈ Θ1 based on the early-
stage data xe, and Q(A) =
∫
A
q(x)dµ(x). Here, we assume that all densities pθ(x) are taken
with respect to the same dominating measure µ.
Proposition 5.2. For any test ϕ(x) of H0 we have BEPϕ = EQ[ϕ(x)], the power of ϕ(x)
against the simple alternative H1 : P = Q. Consequently, a test ϕ(x) maximizes the BEP
among all α-level tests if and only if it maximizes the power EQ[ϕ(x)] among all α-level tests.
Proof. By Fubini’s theorem, the BEP of a test ϕ(x) can be written as
BEPϕ =
∫
Θ1
piϕ(θ)p(θ|xe)dθ =
∫
Θ1
[∫
ϕ(x)pθ(x)dµ(x)
]
p(θ|xe)dθ
=
∫
ϕ(x)
[∫
Θ1
pθ(x)p(θ|xe)dθ
]
dµ(x) =
∫
ϕ(x)q(x)dµ(x) · P (H1|xe)
= EQ[ϕ(x)] · P (H1|xe).
Without loss of generality, to derive a maximum-BEP test we assume that µ is invariant
with respect to permutations of the treatment assignments.
Using Propositions 5.1 and 5.2, we can now prove that it is possible to construct a
maximum-BEP test which depends on the data x only through the marginal likelihood
m(x) =
∫
Θ1
L(θ;x)p(θ|xe)dθ. (6)
Since m(x) does not depend on the censoring distribution functions Gi(t) which appear
in Equation 1, the censoring mechanism is irrelevant to identify the optimal test. Note,
however, that the censoring mechanism still determines the BEP.
9
Proposition 5.3. Given the early-stage data xe, the α-level permutation test based on the
marginal likelihood T (x) = m(x) maximizes the BEP among all α-level tests of H0.
Proof. By Proposition 5.1, the α-level permutation test ϕ′(x) based on the test statistic
T ′(x) = q(x) maximizes the power EQ[ϕ(x)] among all α-level tests of H0. By Proposition
5.2, ϕ′(x) has maximum BEP among all α-level tests of H0. It now suffices to show that
ϕ′(x) = ϕ(x) for all x such that q(x) > 0, where ϕ(x) is the α-level permutation test based on
T (x) = m(x). To do so, note that, by Equation 1, if q(x) > 0, then m(x) > 0 as well, and the
ratio q(x)/m(x) is invariant with respect to permutations of the treatment arm assignments.
Indeed, censoring times and treatment assignments are independent. The thesis now follows
because q(t, d, aσ) ∝ m(t, d, aσ) for all permutations σ.
Since randomized tests are not used in applications, we will consider the non-randomized
version ϕ′(x) = I
{
m(x) > m(kα)(x)
}
of the test ϕ(x) from Theorem 5.3. Since ϕ′(x) ≤ ϕ(x),
ϕ′(x) is α-level for H0, although it may not achieve the maximum BEP. Nevertheless, ϕ′(x)
still provide a useful benchmark for other tests of H0, as its BEP is close to optimal for
large n. In fact, in the Appendix, Proposition 9.1, we show that, under mild conditions, 0 ≤
BEPϕ−BEPϕ′ ≤ f(α, r, n), where the bound is a known function such that f(α, r, n)→ 0 as
n→ +∞ for all fixed levels α and randomization probabilities r. In such cases, a moderate
size n is sufficient to obtain a good approximation.
The non-randomized test ϕ′(x) coincides with the non-randomized procedure which re-
jectsH0 whenever when the permutation p-value ppv(x) =
∑
pi I{m(t, d, api) ≥ m(t, d, a)} /n!,
is less or equal than α (Lehmann and Romano, 2006, Section 15.2.1). Although n! will
typically be too large to compute the ppv(x) exactly, the benchmark test can be im-
plemented by a conditional Monte Carlo approximation. Accordingly, given x, a large
random sample of permutations pi1, . . . , piB (B = 10
3, say) is used to compute the esti-
mate p̂pv(x) =
∑B
i=1 I{m(t, d, apii) ≥ m(t, d, a)} /B. The hypothesis H0 is then rejected if
p̂pv(x) ≤ α (Pesarin and Salmaso, 2010, Section 1.9.3).
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6 The piecewise exponential model
Because of its flexibility and tractability, to implement our maximum-BEP test we use a
piecewise exponential model (Benichou and Gail, 1990). In the piecewise exponential model,
the hazard function ha(t; θ) is constant over a fixed partition τ0 = 0 < τ1 < · · · < τk < +∞ =
τk+1 of the time axis. In particular, ha(t; θ) = θa,j if t ∈ [τj−1, τj) with j = 1, . . . , k + 1,
t ∈ R+, arms a = 0, 1, and θ = (θ0,1, . . . , θ0,k+1, θ1,1, . . . , θ1,k+1) ∈ Θ = (0,+∞)2(k+1).
The likelihood function of the piecewise exponential model depends on a simple set of
sufficient statistics. Given data x = (t, d, a), let sa,j =
∑n
i=1 max(0,min(τj − τj−1, ti −
τj−1))I{ai = a} be the total time at risk spent in the interval [τj, τj+1) by patients in arm a.
Additionally, let ya,j =
∑n
i=1 diI{ai = a, τj−1 ≤ ti < τj} be the number of events observed
during [τj−1, τj) in arm a. Then, the likelihood is
L(θ;x) =
1∏
a=0
k+1∏
j=1
θ
ya,j
a,j exp(−θa,jsa,j).
For convenience, we use a conjugate prior p(θ). This is obtained by letting all θa,j
be independent and distributed as a gamma random variable with shape parameter ua,j
and rate parameter va,j. With this choice, the distribution p(θ|xe) presents independent
θa,j components which are gamma distributed with shape parameter ua,j + ye,a,j and rate
parameter va,j+se,a,j, where the ye,a,j and se,a,j are the sufficient statistics of xe. The marginal
likelihood m(x) needed to implement the maximum-BEP test can thus be obtained explicitly
from Equation 6:
m(x) =
1∏
a=0
k+1∏
j=1
(
va,j + se,a,j
va,j + se,a,j + sa,j
)ua,j+ye,a,j+ya,j Γ(ua,j + ye,a,j + ya,j)
Γ(ua,j + ye,a,j)
, (7)
where Γ(z) is the gamma function.
As an example, Figure 1a shows the posterior means of the survival probabilities in
the nivolumab or SOC arm of CheckMate 141 obtained from the piecewise exponential
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model. For all j = 1, . . . , k = 4, we conveniently defined τj to be the j-th quintile of the
distribution of follow-up times in the SOC arm. In different words, the prior model is chosen
by peaking at the early stage trial. Additionally, we specify gamma priors on the θa,j with
ua,j = va,j = 10
−3 for all a and j. The posterior estimates (Figure 1a) reflect the delayed
separation in the Kaplan-Meier curves, as the estimated survival probabilities diverge only
after 4 months of follow-up.
7 Application: trials with delayed treatment effects
7.1 Simulation study
As an illustration, we use CheckMate 141 data to simulate a large number of phase II and
III trials with delayed treatment effects. In these simulations, we compare different tests
with respect to their probability of rejecting the hypothesis of no treatment effects at the
end of the phase III trial. We consider Mantel’s log-rank test and several others which
account for delayed treatment effects: i) a lagged log-rank test that ignores the first 10%
of observed follow-up times (Zucker and Lakatos, 1990); ii) the Fleming-Harrington G0,1
test, which gives more weight to late events (Fine, 2007); iii) the adaptive log-rank of Yang
and Prentice (2010), which weights events according to a preliminary estimate of the hazard
functions; and iv) a test of the difference in Restricted Mean Survival Times (RMSTs) across
study arms (Huang and Kuan, 2018). We also implement the maximum-BEP test (using
the conditional Monte Carlo approach of Section 5) based on phase II data. For all tests,
we consider α = 0.05 and a two-sided alternative hypothesis.
To simulate a trial of size n, we first sample with replacement n patients from the Check-
Mate 141 data. Then, depending on patient’s membership arms, we generate the corre-
sponding survival times from the Kaplan-Meier curves of Figure 1a. Assuming a maximum
follow-up of 15 months, we generate patient’s censoring times by sampling independently
from the empirical censoring distribution (Efron, 1981).
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Using this approach, we iterate the following steps 10,000 times: i) we simulate a phase
II trial of approximately half the size of CheckMate 141 (ne = 180); ii) using the simulated
phase II data xe, we determine the marginal likelihood m(x) for the piecewise exponential
model (Equation 7); we fix the τjs at the quintiles of the follow-up times in the SOC arm
from xe and specify the same gamma prior (ua,j = va,j = 10
−3) for the parameters θa,j as
in Section 6; iii) we simulate a subsequent phase III study, generating a phase III dataset
x with sample size n = 361; iv) we apply the test to data x and record the corresponding
accept-reject decision. The proportion of rejections across iterations is the Monte Carlo
estimate of a test’s rejection probability.
Figure 1b reports the estimated rejection probabilities for each testing procedure. The
maximum-BEP permutation test based on phase II data has the highest probability of re-
jecting the null hypothesis (approximately 0.90). The G0,1 test and the lagged log-rank test
have both estimated rejection probabilities of about 0.87. The adaptive log-rank and RMST
tests have lower rejection probabilities, 0.77 and 0.66 respectively. Mantel’s log-rank test
has the lowest estimated rejection probability, i.e. 0.60, a third less than the one achieved
by our test and the nominal 90% power in the sample size calculations of CheckMate 141
(Ferris et al., 2016). This finding is consistent with previous studies, which highlighted how
the log-rank test may suffer a severe loss of power when treatment effects are delayed (Fine,
2007; Chen, 2013; Alexander et al., 2018).
7.2 Robustness analysis
We consider three additional simulation scenarios in which the outcome distributions in
phase II and III are not identical. In all scenarios, the distribution of the phase II data xe
is the same as in Section 7.1, while the distribution of the phase III data x is different. In
Scenario 1, the dataset x is generated from the predictive distribution q(x) (see Equation
5): a value θ′ is first sampled from p(θ|xe), then x is generated from the distribution pθ′(x).
Here we assume r = 2/3 as in CheckMate 141 and that censoring can only occur after 15
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months of follow-up. Proposition 5.2 indicates that, in this scenario, our permutation test
has the highest expected power. Scenarios 2 and 3 instead represents two settings in which
our test may suffer from a loss of power. In Scenario 2, x is generated by a different piecewise
exponential model than the one used to construct the benchmark test. The phase III delay
in treatment effects is shorter than expected from phase II data. Specifically, x is generated
by a model with only one cut-point, fixed at τ1 = 2 months, whose parameters are set equal
to the maximum likelihood estimates obtain from CheckMate 141 data. Scenario 3 is similar,
but the cut-point is fixed at τ1 = 8 months to represent longer phase III delays than those
expected from phase II data.
Figure 1c shows the results of the robustness analysis. As expected, in Scenario 1 our
permutation test has a much higher rejection probability than all other tests (0.98). Instead,
its performance is sub-optimal in Scenario 2 and 3. Although in Scenario 3 our permutation
test may be considered comparable with the others (rejection probability equal to 0.29), in
Scenario 2 it has the lowest rejection probability (0.84, compared to 0.90 for the Mantel’s
log-rank). These findings support the intuition that the power of the maximum-BEP test
depends on how well it is possible to predict the phase III data on the basis of prior infor-
mation. If the phase II and III trial populations are markedly different, then a test specified
using phase II data may perform poorly in the phase III study.
8 Generalization to stratified designs
Treatment effects are often expected to vary across patients’ groups defined, for example,
by gender or biomarkers. In such cases one can stratify patients with respect to covariates
measured before randomization. We focus on the primary goal of testing whether the ex-
perimental treatment has no effects across all strata or if it is effective at least in some of
the strata (alternative hypothesis), for example in one or multiple subgroups defined by a
relevant biomarker (Freidlin et al., 2010).
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Our approach can be easily generalized to this setting. For simplicity, we suppose each
patient i = 1, . . . , n is categorized by a binary covariate zi = 0, 1, presence (zi = 1) or
absence (zi = 0) of some marker. Data x becomes x = (t, d, a, z), where z = (z1, . . . , zn) ∈
{0, 1}n. Similar to the previous paragraphs we assume that censoring is non-informative and
independent of treatment assignments conditionally on z1, . . . , zn (Heitjan and Rubin, 1991).
To illustrate, we specify a piecewise-exponential model ha(t; θ, z) for the hazard function
in arm a = 0, 1 for patients with marker level z = 0, 1 (Freidlin et al., 2010): ha(t; θ, z) = θa,z,j
for all t ∈ [τj−1, τj). The prior remains nearly identical to the previous sections. In particular,
the marginal likelihood m(t, d, a, z), similar to Equation 6, has a closed form expression.
We specify the null hypothesis H ′0 : P ∈ P ′0, where P ′0 is the class of all distributions which
are invariant with respect to permutations of the treatment assignment a within strata of z.
More precisely, P ∈ P ′0 if and only if p, the density of P , satisfy p(t, d, a, z) = p(t, d, aσ, z)
for all permutations σ of (1, . . . , n) such that zσ(i) = zi for all i = 1, . . . , n.
With a simple modification, Proposition 5.3 still holds with this new definition of the null
hypothesis. Previously, the maximum-BEP permutation test computed the distribution of
m(x) under H ′0 by considering all permutations of the treatment arm indicators a1, . . . , an.
In the stratified case, only permutations σ of (1, . . . , n) such that zσ(i) = zi for all i = 1, . . . , n
are considered. If Σ(z) is the set of all such σ, then the permutation p-value associated to
the maximum-BEP test is given by ppv(x) =
∑
σ∈Σ(z) I{m(t, d, aσ, z) ≥ m(t, d, a, z)}/|Σ(z)|,
where |Σ(z)| = (∑ni=1 zi)!(n−∑ni=1 zi)!.
8.1 Simulation study of biomarker-stratified designs
Similarly as in Section 7.1, we use CheckMate 141 data to simulate many phase II and III
trials where 50% of patients express (zi = 1) a marker predictive of treatment effects (Patel
and Kurzrock, 2015). From the simulations, we compare different tests for the final analysis
of the phase III trial, each accounting for patients’ maker values. Specifically, we consider
four (5%-level) tests of H ′0: i) a test based on a stratified Cox proportional hazards model
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(a common approach in this setting; Mehrotra et al., 2012); ii) the procedure obtained by
first performing separate log-rank tests within marker strata and then combining their p-
values using Bonferroni’s correction (another common approach; Freidlin et al., 2014); iii)
the test obtained by estimating separate log-normal accelerated failure time (AFT) models
(Kalbfleisch and Prentice, 2002, Chapter 2) within marker strata, testing the statistical
significance of their regression coefficients, and combining the results using Bonferroni’s
correction; and, lastly, iv) our maximum-BEP test, tailored to simulated phase II data.
In more detail, we simulate 10,000 phase II (ne = 180) and III (n = 361) trials from
CheckMate 141 data for each of 3 scenarios. In Scenario 1, the survival distribution in phase
II and III trials is the same. Here, the survival time of a patient in arm a = 0 or with marker
z = 0 (respectively, in arm a = 1 with marker z = 1) is generated from the SOC (nivolumab)
Kaplan-Meier curve in Figure 1a. Censoring times are generated as in Section 7.1.
In Scenarios 2 and 3, phase II data are generated as before, but the outcome distribution
in phase III is different. In Scenario 2, phase III data are generated assuming proportional
hazards within levels of z. Specifically, the survival time of a patient in arm a = 0 or with
marker z = 0 (respectively, in arm a = 1 with z = 1) is simulated from an exponential
distribution, fixed at the corresponding estimate from the SOC (respectively, nivolumab)
arm of CheckMate 141. Scenario 3 is similar, but we do not assume proportional hazards in
the strata of z. Rather, phase III data are generated as in Scenario 2, but using stratum-
specific log-normal distributions (Kalbfleisch and Prentice, 2002).
Figure 2 shows the results from the simulations. For Scenario 1, the estimated rejection
probabilities are 0.18 for the stratified Cox model, 0.26 for the Bonferroni-based log-rank
test, 0.08 for the Bonferroni-based AFT test, and 0.49 for our test tailored to early-stage
data. In Scenario 2, akin as in Section 7.2, the test based on a stratified Cox proportional
hazards model and the Bonferroni-based log-rank test outperform our tailored test, as their
estimated rejection probabilities are 0.21, 0.29, and 0.17, respectively. Instead, in Scenario
3, our tailored test has an estimated rejection probability (0.32) higher than that of the
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other tests not tailored to prior data, although its power advantage is reduced compared to
Scenario 1. These results confirm that, in late-stage trials, a benefit can be attained when
prior data is used to optimize hypothesis testing, but this benefit can be reduced when the
early- and late-stage survival distributions are not homogeneous.
[FIGURE 2 ABOUT HERE]
9 Discussion
Data from previous studies should be routinely used to design late-stage clinical trials. This is
especially relevant when standard assumptions, such as the proportional hazards assumption,
might not hold. Our approach allows to specify a test for final analyses that accounts for the
deviations from proportional hazards suggested by prior data and satisfies the requirements
of regulatory agencies (Ventz and Trippa, 2015). The test maximizes a decision-theoretic
criteria leveraging on prior data and it is of α-level for an interpretable null hypothesis.
In practice, we used a piece-wise exponential model with fixed cut-points to implement
our procedure (Benichou and Gail, 1990). More generally, the positions of the cut-points
could be assigned a prior distribution (Demarqui et al., 2008). Other models, parametric or
non-parametric, could also be used (Ibrahim et al., 2013; Ghosal and van der Vaart, 2017).
Regardless of the chosen model, to implement our test it is necessary to compute the
marginal likelihood of late-stage data. This may be complicated for non-conjugate models,
but many methods are available to approximate it (Pajor et al., 2017).
Although we derived our test assuming a single early-stage dataset, the use of multiple
prior data sources may provide better outcome predictions for late-stage trials. Our ap-
proach can incorporate multiple prior datasets using power priors (Ibrahim et al., 2000) or
hierarchical models (Spiegelhalter et al., 2004).
Our simulations, based on data from the CheckMate 141 trial, confirm that weighted
log-rank tests can outperform other tests in presence of delayed treatment effects. However,
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these tests depend on a set of tuning parameters, such as the duration of the lag time for
lagged log-rank tests or the ρ and δ coefficients of the Gρ,δ Fleming-Harrington family, which
may be hard to tune. Instead, our approach directly translates early-stage data into a test
procedure for the late-stage trial.
Robustness analyses highlight how the performance of our approach is dependent on the
consistency of outcome data and the similarity of enrolled populations between phase II and
phase III trials. Ensuring the transportability of results to subsequent trials remains a major
concern in the design of exploratory clinical trials (Wang et al., 2006).
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Additional supporting information may be found online in the Supporting Information sec-
tion at the end of the article. Supplementary material includes data and code to replicate
the simulation studies of Sections 7.1, 7.2, and 8.1. This is also available at the following
web address: https://github.com/andreaarfe/Bayesian-optimal-tests-non-PH.
Appendix
Denote with Π(x) the set of all
(
n∑n
i=1 ai
)
distinct datasets obtained from x = (t, d, a) by
permuting the elements of a in all possible ways. Here, we will assume that when q(x) > 0
the inequality m(x1) 6= m(x2) holds for all x1, x2 ∈ Π(x) such that x1 6= x2.
Proposition 9.1. Let ϕ(x) be the α-level permutation test of Proposition 5.3 and ϕ′(x) its
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non-randomized version. Then
0 ≤ BEPϕ −BEPϕ′ ≤ f(α, r, n) = (1− r)
n
α
n∑
s=0
(
r
1− r
)s
Proof. By Proposition 5.2, 0 ≤ BEPϕ − BEPϕ′ = EQ[ϕ(x) − ϕ′(x)] ≤ Q(E), where E is
the set of all x such that m(x) = m(kα)(x). Proceeding as in Section 5.9 of Lehmann and
Romano (2006),
Q(E) =
∫ ∑
σ I
{
m(t, d, aσ) = m
(kα)(x)
}
q(t, d, aσ)∑
σ q(t, d, aσ)
dQ(x), (8)
where both sums extend over all n! permutations σ of (1, . . . , n). If q(x) > 0, then
∑
σ I
{
m(t, d, aσ) = m
(kα)(x)
}
q(t, d, aσ)∑
σ q(t, d, aσ)
=
∑
σ I
{
m(t, d, aσ) = m
(kα)(x)
}
m(t, d, aσ)∑
σm(t, d, aσ)
≤
∑
σ I
{
m(t, d, aσ) = m
(kα)(x)
}
m(t, d, aσ)∑
σ I{m(t, d, aσ) ≥ m(kα)(x)}m(t, d, aσ)
≤
∑
σ I
{
m(t, d, aσ) = m
(kα)(x)
}
m(kα)(x)∑
σ I{m(t, d, aσ) ≥ m(kα)(x)}m(kα)(x)
=
∑
σ I
{
m(t, d, aσ) = m
(kα)(x)
}∑
σ I{m(t, d, aσ) ≥ m(kα)(x)}
=
#{j : m(j)(x) = m(kα)(x)}
#{j : m(j)(x) ≥ m(kα)(x)} ,
where the first equality follow because the ratio q(x)/m(x) is invariant with respect to
permutations σ of a. Now, by the definitions of m(kα)(x) and kα, the denumerator of the
last fraction is greater or equal than αn!. Instead, the numerator is equal to n!/
(
n∑n
i=1 ai
)
, as
i) m(kα)(x) = m(xα) for some xα ∈ Π(x), ii) for each x′ = (t, d, a′) ∈ Π(x) there are exactly
n!/
(
n∑n
i=1 ai
)
permutations σ such that x′ = (t, d, aσ), and iii) m(x) assumes distinct values
on distinct points of Π(x), by assumption. Thus, by Equation 8,
Q(E) ≤ EQ
[
1(
n∑n
i=1 ai
)
α
]
=
n∑
s=0
1(
n
s
)
α
(
n
s
)
rs(1− r)n−s = f(α, r, n).
This concludes the proof.
In general, the approximation provided by Proposition 9.1 will be fairly accurate. For
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example, if α = 0.05 and r = 1/2, the difference f(α, r, n) between BEPϕ and BEPϕ′ is
2−n(n+1)/α < 10−3 for all n ≥ 15. For r 6= 1/2 it is f(α, r, n) = [(1−r)n+1−rn+1]/α(1−2r);
for r = 2/3, the value considered in Section 7, f(α, r, n) < 10−3 for all n ≥ 25.
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Figure 1: Panel a, reconstructed Kaplan-Meier curves from the CheckMate 141 trial and
posterior estimates obtained from the piecewise exponential model (Section 6). Panel b,
Monte Carlo estimates of the rejection probability of selected tests (Section 7.1). Panel
c, results of the robustness analysis (Section 7.2). Estimates in Panels (b) and (c) are
based on 104 simulated trials. Legend: permutation, maximum-BEP test of Section 5 based
on the piecewise exponential model (highlighted in red); adaptive, adaptive log-rank test of
Yang and Prentice (2010); mantel, classical Mantel’s log-rank test; G0,1, Fleming-Harrington
weighted log-rank test; lagged, lagged-log rank that ignores the first 10% of observed follow-
up times (Zucker and Lakatos, 1990), RMST, test of the difference in restricted mean survival
times (Huang and Kuan, 2018).
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Figure 2: Monte Carlo rejection probability estimates obtained for the 3 scenarios of Section
8.1, using selected tests that account for a binary predictive marker. All estimates are based
on 104 simulated trials. Legend: permutation, maximum-BEP test of Section 8 based on
the piecewise exponential model (highlighted in red); stratum-specific log-rank, Bonferroni
combination of two stratum-specific log-rank tests (Freidlin et al., 2014); stratum-specific
AFT, Bonferroni combination or two stratum specific tests based on a log-normal accelerated
failure time models (Kalbfleisch and Prentice, 2002); stratified Cox, test based on a stratified
Cox proportional hazards model (Mehrotra et al., 2012).
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